Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Nike
NKE
5
Amazon
AMZN
JP Stock MarketDetailed Quotes
4588 Oncolys BioPharma
- 532
- -17-3.10%
20min DelayMarket Closed Apr 4 15:30 JST
13.28BMarket Cap-6.89P/E (Static)
551High505Low1.43MVolume543Open549Pre Close748.40MTurnover91852wk High6.27%Turnover Ratio24.96MShares42052wk Low-77.17EPS TTM12.10BFloat Cap4410Historical HighLossP/E (Static)22.75MShs Float401Historical Low-77.17EPS LYR8.38%Amplitude--Dividend TTM4.81P/B100Lot Size--Div YieldTTM
Oncolys BioPharma Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -50.21%31.38M | 11.93%31.38M | 0 | -93.54%63.04M | 0 | 0 | -87.97%28.04M | -81.88%35M | 51.94%976.18M | -40.87%191.67M |
| Cost of revenue | 0 | 0 | 0 | -94.91%32.43M | 0 | 0 | 0 | -50.59%32.43M | 43.73%637.7M | -44.58%163.34M |
| Gross profit | 2.55%31.38M | 11.93%31.38M | 0 | -90.96%30.6M | 0 | 0 | -74.96%28.04M | -97.99%2.57M | 70.26%338.49M | -3.70%28.34M |
| Operating expense | -12.64%1.71B | -26.11%445.88M | 15.46%378.87M | 27.06%1.96B | 109.49%618.95M | 17.43%410.05M | 56.28%603.45M | -35.94%328.15M | -6.68%1.54B | -43.22%295.46M |
| Operating profit | 12.88%-1.68B | 27.96%-414.5M | -16.37%-378.87M | -60.23%-1.93B | -131.71%-618.95M | -47.24%-410.05M | -109.89%-575.41M | 15.38%-325.58M | 17.19%-1.2B | 45.59%-267.13M |
| Net non-operating interest income (expenses) | -43.89%-20.05M | -421.40%-2.83M | -337.39%-3.09M | -311.25%-13.93M | -398.88%-4.01M | -862.20%-8.68M | 42.46%-542K | 4.72%-706K | 78.48%-3.39M | 46.86%-803K |
| Non-operating interest income | 45.42%2.15M | 37.76%529K | 247.65%518K | 151.28%1.48M | 262.79%468K | 172.41%474K | 193.13%384K | -2.61%149K | 18.83%587K | 15.18%129K |
| Non-operating interest expense | 27.62%4.6M | 12.85%1.05M | 33.33%1.14M | -8.69%3.6M | -11.70%823K | -7.25%998K | -13.70%926K | -1.04%855K | -5.37%3.95M | -4.70%932K |
| Total other finance cost | 49.04%17.6M | --2.31M | --2.47M | 39,253.33%11.81M | --3.65M | ---- | ---- | ---- | -99.75%30K | --0 |
| Net investment income | 58.62%43.78M | -6.30%29.86M | 484.84%18.67M | -55.94%27.6M | 46.47%-20.08M | -20.12%12.62M | -29.14%31.86M | -91.89%3.19M | 67.62%62.64M | -524.70%-37.51M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | 21.40%-17.1M | 0 | 0 | -227.99%-21.76M | -397.34%-21.9M | 0 | 0 | 136K | 185.68%17M | 77.81%-4.4M |
| Less:Other special charges | ---- | ---- | ---- | 99.36%-136K | --0 | --0 | --0 | ---136K | ---21.41M | --0 |
| Less:Write off | -21.89%17.1M | ---- | ---- | 397.34%21.9M | ---- | ---- | ---- | ---- | -77.81%4.4M | ---- |
| Other non-operating income (expenses) | -349.42%-6.24M | 114.09%2.5M | 0 | 868.52%2.76M | 73.88%-17.76M | 92.28%-3.12M | ||||
| Income before tax | 13.15%-1.68B | 28.41%-389.71M | -12.49%-363.29M | -68.90%-1.94B | -112.47%-664.93M | -52.82%-403.34M | -125.98%-544.35M | 1.60%-322.96M | 28.90%-1.15B | 50.70%-312.96M |
| Income tax | 28.61%3.76M | 29.13%931K | 27.72%940K | -0.20%2.93M | 0.00%733K | -0.27%736K | -0.28%721K | -0.27%736K | -21.29%2.93M | -21.86%733K |
| Net income | 13.09%-1.68B | 28.33%-390.64M | -12.52%-364.23M | -68.72%-1.94B | -112.20%-665.66M | -52.67%-404.08M | -125.60%-545.07M | 1.60%-323.69M | 28.88%-1.15B | 50.66%-313.69M |
| Net income continuous operations | 13.09%-1.68B | 28.33%-390.64M | -12.52%-364.23M | -68.72%-1.94B | -112.20%-665.66M | -52.67%-404.08M | -125.60%-545.07M | 1.60%-323.69M | 28.88%-1.15B | 50.66%-313.69M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 13.09%-1.68B | 28.33%-390.64M | -12.52%-364.23M | -68.72%-1.94B | -112.20%-665.66M | -52.67%-404.08M | -125.60%-545.07M | 1.60%-323.69M | 28.88%-1.15B | 50.66%-313.69M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 13.09%-1.68B | 28.33%-390.64M | -12.52%-364.23M | -68.72%-1.94B | -112.20%-665.66M | -52.67%-404.08M | -125.60%-545.07M | 1.60%-323.69M | 28.88%-1.15B | 50.66%-313.69M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 29.15%-77.17 | 40.51%-18.72 | 2.41%-18.24 | -64.26%-108.92 | -97.52%-35.77 | -50.46%-22.99 | -125.75%-31.47 | 1.53%-18.69 | 30.57%-66.31 | 51.16%-18.11 |
| Diluted earnings per share | 29.15%-77.17 | 40.51%-18.72 | 2.41%-18.24 | -64.26%-108.92 | -97.52%-35.77 | -50.46%-22.99 | -125.75%-31.47 | 1.53%-18.69 | 30.57%-66.31 | 51.16%-18.11 |
| Dividend per share | ||||||||||
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |